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Summary
The effect of lipopolysaccharide (LPS) on platelet aggregation is still 
controversial. We performed in vitro and ex vivo studies in controls and 
in patients with community-acquired pneumonia (CAP) to assess the ef-
fect of LPS on platelet activation (PA). LPS (15–100 pg/ml) significantly 
increased PA only if combined with sub-threshold concentrations (STC) 
of collagen or ADP; this effect was associated with increased platelet 
H2O2 production, Nox2 activation, PLA2 phosphorylation, thromboxane 
(Tx)A2 and 8-iso-PGF2α-III, and was inhibited by aspirin, TxA2 receptor 
antagonist or by Toll-like receptor 4 blocking peptide (TLR4bp). Analysis 
of up-stream signalling potentially responsible for Nox2 and PLA2 acti-
vation demonstrated that LPS-mediated PA was associated with phos-
phorylation of AKT, p38 and p47phox translocation. In 10 consecutive 
CAP patients serum endotoxins were significantly higher compared to 
10 controls (145 [115–187] vs 18 [6–21] pg/ml; p<0.01). Ex vivo study 
showed that agonist-stimulated platelets were associated with en-
hanced PA (p<0.01), Toll-like receptor 4 (TLR4) expression (p<0.05), 
TxA2 (p<0.01) and 8-iso-PGF2α-III (p<0.01) production in CAP patients 
compared to controls. The study provides evidence that LPS amplifies 
the platelet response to common agonists via TLR4-mediated eicosan-
oid production and suggests LPS as a potential trigger for PA in CAP.
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Introduction
Systemic inflammation secondary to an infection may be associ-
ated to artery and venous thrombosis; thus, recent studies have 
shown that patients with sepsis secondary to community-acquired 
pneumonia (CAP) are characterised by an enhanced risk of myo-
cardial infarction (MI) and stroke in the early phase of hospitali-
sation (1). Such cardiovascular complications have a negative im-
pact in short- and long-term follow-up as they enhance the risk of 
mortality and recurrence of cardiovascular events (2). Among the 
mechanisms potentially accounting for the association between 
sepsis and thrombosis, platelets may play a central role. Thus, a re-
cent study from our group demonstrated an enhanced risk of MI 
in CAP patients with systemic signs of platelet activation; more in 
particular we found that platelet thromboxane(Tx)A2 over-pro-
duction and in vivo platelet activation were significantly associated 
with MI. Platelet activation was suggested to be dependent upon 
infection severity but the intrinsic mechanism was not identified 
(3). Recent studies suggested that, during infection, patients dis-
close a gut barrier dysfunction, which could cause lipopolysac-
charide (LPS) translocation into systemic circulation (4). Bacterial 
LPS could account for platelet activation but, so far, there is uncer-
tainty as to whether LPS is actually capable of activating platelets. 
Thus experimental studies demonstrated that LPS may have null, 
inhibitory and pro-aggregating effects but the reason for these dis-
crepancies is still unclear (5, 6). A recent study by Zhang et al. (7) 
shed light on this issue by demonstrating that LPS per se is unable 
to aggregate platelets but amplifies the platelet response to com-
mon agonists upon interaction with its Toll-like receptor 4 (TLR4) 
(7). The study, however, did not fully solve this issue because LPS 
concentration used for in vitro experiments was in a range be-
tween 1 and 10 µg/ml, which is much higher than that potentially 
achievable in human circulation during infections or sepsis (8). 
Based on this, we undertook an in vitro and ex vivo study with the 
main objective to investigate if endotoxins are implicated in pla-
telet aggregation and the mechanism potentially accounting for it 
in CAP patients. The study encompassed two phases: 1) in vitro 
experiments to assess if LPS, in a range of concentrations detected 
in blood of CAP, was capable of activating platelets, and 2) ex vivo 
platelets aggregation in CAP patients and controls.
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Materials and methods
In vitro study
Platelet aggregation
Citrated blood samples were taken between 8 and 9 am from 
healthy subjects (HS) who had fasted for at least 12 hours (h). To 
obtain platelet-rich plasma (PRP), citrated blood samples were 
centrifuged for 15 minutes (min) at 180g. To avoid leukocyte con-
tamination, only the top 75 % of the PRP was collected according 
to Pignatelli et al. (9).
To obtain washed platelets, PRP was treated with acid citrate 
dextrose (ACD) (10/1 v/v), centrifuged at 300g for 10 min (twice) 
and suspended in fatty acid free Tyrode’s buffer (2×108 platelets/
ml). Before activation, samples were pre-incubated (20 min at 
37 °C) with TLR4 inhibitor peptide, that inhibits TLR4 signalling 
by blocking interactions between TLR4 and its adaptors proteins 
(4 µmol/l, Novus Biologicals, Littleton, CO, USA), or control pep-
tide (CP) (4 µmol/l, Novus Biologicals), aspirin (ASA), which in-
hibits the COX-1 pathway preventing TxA2 biosynthesis (100 
µmol/l) (9) or SQ29548, a TxA2/isoprostane receptor inhibitor (0.1 
µmol/l, Calbiochem, San Diego, CA, USA) (9) or Nox2dstat, the 
most specific and efficacious Nox inhibitor that specifically in-
hibits interactions between Nox2 and p47phox (50 µmol/l, Anas-
pec, Fremont, CA, USA) (10). To study the intra-signalling path-
way, we used the p38 inhibitor SB202190 (5 µmol/l, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) as p38 is involved in ROS 
(11) and eicosanoids production (12). After incubation, samples 
were treated with LPS from Escherichia coli 0111:B4 (Sigma Cat# 
L3015, protein contamination <1 %, Sigma Aldrich, St. Louis, MO, 
USA) (15–100 pg/ml) 5 min before activation with sub-threshold 
(STC) concentration of agonists such as collagen (0.25 µg/ml, 
Mascia Brunelli, Milan, Italy) or ADP (2 µmol/l) for 10 min at 
37 °C. STC concentration of agonists was defined as the highest 
concentration that elicited <20 % platelet aggregation. After stimu-
lation with agonists, samples were centrifuged for 3 min at 3000g. 
Supernatants were stored at –80 °C for analysis of sNox2-dp, TxB2, 
8-Iso-PGF2α -III and pellets were stored at –80 °C for analysis of 
AKT, cPLA2, p38 phosphorylation and p47phox translocation.
The intra-assay and inter-assay coefficients of variation were 
5.7 % and 6.8 %, respectively.
H2O2 production
Hydrogen peroxide (H2O2) was evaluated by a Colorimetric De-
tection Kit (Arbor Assays, Ann Arbor, MI, USA) and expressed as 
µmol/l. Intra-assay and inter-assay coefficients of variation were 
2.1 % and 3.7 %, respectively.
Platelet soluble Nox2-derived peptide
Extracellular levels of soluble Nox2-derived peptide (sNox2-dp), a 
marker of NADPH oxidase activation, were detected by ELISA as 
previously described (13). The peptide was recognised by the spe-
cific monoclonal antibody against the amino acidic sequence 
(224–268) of the extra membrane portion of Nox2 (catalytic core 
of NADPH oxidase), which was released in the medium upon pla-
telet activation. Values were expressed as pg/ml; intra-assay and 
inter-assay coefficients of variation were 5.2 % and 6 %, respect-
ively.
Platelet and urinary TxB2 and 8-Iso-PGF2α assays
Platelet TxA2 was analysed as previously described (14) by evaluat-
ing its stable metabolite TxB2 by ELISA commercial kit (Cusabio, 
College Park, MD, USA) and expressed as pg/ml ×108 cells. Intra- 
and inter-assay coefficients of variation for TxB2 were 4.0 % and 
3.6 %, respectively. Urinary 11-dehydro TXB2 was analysed by 
ELISA commercial kit (DRG International, Springfield, NJ, USA) 
and expressed as pg/mg creatinine.
Platelet and urinary isoprostane (8-iso-PGF2α -III) were 
measured by the enzyme immunoassay method (DRG Inter-
national) and expressed as pmol/l and pg/mg creatinine, respect-
ively. Intra-assay and inter-assay coefficients of variation were 
5.8 % and 5.0 %, respectively.
Endotoxin levels
Endotoxin (LPS) serum and plasma levels were measured by 
ELISA Kit (Cusabio). Antibody specific for LPS has been pre-
coated onto a microplate and 100 µl of standards or sample was 
plated for 2 h at room temperature. After incubation, samples were 
read at 450 nm. Values were expressed as pg/ml; intra-assay and 
inter-assay coefficients of variation were 8 % and 10 %, respect-
ively.
Membrane and cytoplasmic proteins extraction
Briefly, the extraction of membrane and cytoplasmic proteins was 
performed by using the ProteoJET Membrane Protein Extraction 
Kit (Fermentas International Inc, Burlington, ON, Canada) as re-
ported by Fortuño et al. (15).
Western blot analysis of TLR4, AKT, cPLA2, p38MAP -
Kinase and p47phox
Platelet pellets were suspended in a 2X Lysis buffer (5 mM EDTA, 
0.15 mol NaCl, 0.1 mol Tris pH 8.0, 1 % triton and 10 µg/ml of 
protease and phosphatase inhibitors cocktail). Equal amounts of 
protein (30 µg/lane) estimated by Bradford protein assay were so-
lubilised in a 2X Laemmli sample buffer containing 20 % of 2-mer-
captoethanol. Proteins were separated by SDS-PAGE on 10 % poly-
acrylamide gel and then electro-transferred to nitrocellulose mem-
branes. After blocking, membranes were incubated with different 
antibodies (all Santa Cruz Biotechnology): mouse monoclonal 
anti-p-AKT antibody raised against an amino acid sequence re-
cognising the phosphorylation in the Ser473 site of AKT; mouse 
monoclonal anti-AKT antibody; polyclonal anti-p-cPLA2 anti-
body raised against an amino acid sequence recognising the phos-
phorylation in the Ser505 site of cPLA2; polyclonal anti-cPLA2 
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antibody; polyclonal anti-p-p38 antibody raised against an amino 
acid sequence recognising the phosphorylation in the Thr180 site 
of p38; polyclonal p38α antibody; mouse monoclonal anti-p47phox 
antibody; polyclonal anti-TLR4 antibody or mouse monoclonal 
anti-β actin antibody and incubated overnight at 4°C. After, the 
membranes were incubated with secondary antibody (Santa Cruz 
Biotechnology, 1:5000) and then the immune complexes were de-
tected by enhanced chemiluminescence substrate. Densitometric 
analysis of the bands was performed using Image J software.
Measurement of [Ca2+]i mobilisation
Platelet [Ca2+]i mobilisation was measured in PRP incubated for 
20 min at 37 °C with 8 µmol/l FLUO 4-acetoxymethyl ester (FLUO 
4-AM; Invitrogen, Carlsbad, CA, USA) in dimethyl sulfoxide. One 
ml of Tyrode buffer was added and the mixture was analysed by 
the Epics XL-MCL Cytometer (Coulter Electronics, Cooper City, 
FL, USA) equipped with an argon laser at 488 nm. The basal fluor-
escence intensity corresponding to FLUO 4-AM was measured for 
1 min in the platelet population identified in the gate as 
CD61-positive events. LPS (15–100 pg/ml) or STC of agonists 
alone or LPS 15 pg/ml in presence of STC of agonists with or with-
out TLR4bp were added and data acquired for 1 min.
Assessment of apoptosis
Apoptosis was determined by staining cells with Annexin V ac-
cording to Hai et al. (16). Briefly, cells were harvested after acti-
vation with LPS (15–100 pg/ml) in presence of STC of collagen or 
ADP. As positive control of apoptosis, cells were treated with 50 
mmol/l of arachidonic acid (AA). After incubation, cells were 
washed twice with cold phosphate-buffered saline and then sus-
pended in 1 ml binding buffer (10 mmol/l HEPES/NaOH (pH 
7.4), 140 mmol/l NaCl, 2.5 mmol/l CaCl2) at a concentration of 
1×106 cells/ml. Platelets were incubated with 5 µl Annexin V (8.3 
mmol/l) (Invitrogen) for 10 min in the dark. Cell fluorescence was 
measured on Epics XL-MCL Cytometer (Coulter Electronics) 
equipped with an argon laser at 488 nm.
Ex vivo study
PA was evaluated in 15 consecutive aspirin-free patients (9 males, 
6 females; age 65.0 ± 9.8 years), who were enrolled in a prospective 
study aimed at assessing the incidence of cardiovascular disease in 
CAP patients (3, 17); 10 age- and sex-matched controls (6 males, 4 
females; age 64.8 ± 11.5 years), not taking antiplatelet drugs were 
used as controls. Patients with CAP and controls were consecu-
tively recruited within a prospective, observational study, which 
was registered at ClinicalTrials.gov (Identifier: NCT01773863) at 
the Internal Medicine ward of “Sapienza” University of Rome. 
CAP patients were part of the SIXTUS study (3), which included 
consecutive patients according to the following criteria after giving 
written informed consent. Patients’ characteristics have been pre-
viously reported (3). Severity of illness at presentation was quanti-
fied by the Pneumonia Severity Index (PSI), a validated prediction 
score for 30-day mortality in patients with CAP. In the same peri-
od of CAP enrolment, 10 hospitalised patients without acute infec-
tions matched for sex, age, and comorbidities were used as con-
trols. Ex vivo PA was performed using citrated blood samples, 
which were taken and treated as above reported.
This study was conducted according to the principles stated in 
the Declaration of Helsinki. The institutional review board ap-
proved this observational study.
Statistical analysis
Categorical variables were reported as counts (percentage). Con-
tinuous variables with normal distribution were expressed as 
means ± standard deviation (SD). Non-parametric variables were 
expressed as median and interquartile range (IQR) or median and 
minimum-maximum values. We tested the independence of cat-
egorical variables by Chi2-test and the normal distribution of pa-
rameters by Kolmogorov-Smirnov test. We used a Student t-test to 
evaluate normally distributed continuous variables. Appropriate 
nonparametric tests were employed for all the other variables. As 
an overall non-parametric ANOVA, the Friedman test for the 
analysis of intragroup variations was used. In cases of significance, 
we compared pair related samples using the Wilcoxon test. The in-
tergroup analysis was performed with the nonparametric 
Mann–Whitney U-test. Only p values lower than 0.05 were re-
garded as statistically significant. All tests were two-tailed and ana-
lyses were performed using computer software packages 
(SPSS-22.0, IBM, NY, USA or R version 2.15.2, R Development 
Core Team, Vienna, Austria).
Results
In vitro study
LPS and platelet aggregation
Platelets from healthy volunteers (n=5, males 3, females 2, age 33.8 
± 4.1) were incubated with scalar concentrations of LPS up to 100 
pg/ml; no significant changes of PA were detected compared to 
baseline for each concentration used (▶ Figure 1 A-B). The choice 
of this concentration was based on serum and plasma LPS analysis 
performed in 10 CAP and 10 controls; serum and plasma endotox-
ins levels were significantly higher in CAP patients compared to 
controls: 145 [115–187] vs 18 [6–21] pg/ml for serum and 107 
[88–131] vs 13 [9–15] pg/ml for plasma (Suppl. Table 1, available 
online at www.thrombosis-online.com).
LPS-treated platelets stimulated with STC of collagen (0.25 
µg/ml), showed a significant increase of PA compared to LPS-
treated platelets alone (▶ Figure 1 A, C). This effect was already 
evident at concentrations of 15 pg/ml. Similar findings were ob-
served with LPS-treated platelets stimulated with STC of ADP (2 
µmol/l) (▶ Figure 1 B-C).
To investigate the underlying mechanism, we pre-treated pla-
telets with different inhibitors, such as TLR4 inhibitor peptide (4 
µmol/l), aspirin (100 µmol/l) or SQ29548 (0.1 µmol/l) which in-
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hibits TxA2 receptors (9) and Nox2ds-tat (50 µmol/l). TLR4 in-
hibitor, aspirin, SQ28548 and Nox2ds-tat significantly inhibited 
PA elicited by LPS-treated platelets added with STC of collagen 
(0.25 µg/ml) or ADP (2 µM) (▶ Figure 1 A-B).
LPS and eicosanoids production
LPS (15–100 pg/ml)-treated platelets did not modify TxB2 (▶ Fig-
ure 2 A-B) or 8-iso-PGF2α-III production (▶ Figure 2 C-D) com-
pared to un-stimulated platelets. LPS-treated platelets stimulated 
with STC of collagen or ADP elicited TxB2 and 8-iso-PGF2α-III 
formation (▶ Figure 2 A-D). This effect was already evident at 
concentrations of 15 pg/ml and was significantly reduced in pla-
telets treated with TLR4 inhibitor (▶ Figure 2 A-D) or aspirin 
(▶ Figure 2 A-B).
LPS and platelet oxidative stress
Platelets incubated with scalar concentrations of LPS (15–100 pg/
ml) did not modify platelet H2O2 production (▶ Figure 3 A-B) and 
Figure 1: LPS and platelet aggregation. Platelets were incubated with 
scalar concentrations of LPS (15–100 pg/ml) and stimulated with or without 
subthreshold concentration (STC) of collagen (0.25 µg/ml) (A) or ADP (2 
µmol/l) (B) in presence or less of TLR4 inhibitor (4 µmol/l), ASA (100 µmol/l), 
inhibitor of TxA2 receptors SQ28548 (0.1 µmol/l), control peptide (CP) (4 
µmol/l) or Nox2ds-tat (50 µmol/l) (A and B) (n=5) (*p<0.05 for paired ana-
lyses; p<0.001 as an overall analysis). Representative tracing of platelet ag-
gregation in presence of LPS (15–100 pg/ml) and STC of collagen or ADP (C).
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sNox2-dp release (▶ Figure 3 C-D) compared to baseline. LPS-
treated platelet stimulated with STC of collagen or ADP, increased 
platelet H2O2 and sNox2-dp release (▶ Figure 3 A-D). This effect 
was already evident at concentrations of 15 pg/ml. In LPS-treated 
platelet stimulated with STC of agonists TLR4 inhibitor signifi-
cantly inhibited H2O2 production (▶ Figure 3 A-B) and sNox2-dp 
release (▶ Figure 3 C-D).
Intra-signalling pathway of platelet activation by LPS
AKT and p38MAPkinase
To investigate upstream pathways implicated in Nox2 activation, 
we analysed the role of AKT and p38MAP kinase, which are both 
implicated in p47phox activation (11, 18). LPS (15–100 pg/ml)-
treated platelets did not show significant changes in AKT and 
Figure 2: LPS and eicosanoids production. TxB2 production was evalu-
ated in platelets incubated with scalar concentrations of LPS (15–100 pg/ml) 
and stimulated with or without subthreshold concentration (STC) of collagen 
(0.25 µg/ml) (A) or ADP (2 µmol/l) (B) in presence or less of TLR4 inhibitor (4 
µmol/l), ASA (100 µmol/l), or control peptide (CP) (4 µmol/l) (A and B) (n=5) 
(*p<0.05 for paired analyses; p<0.001 as an overall analysis). 8-iso-
PGF2α-III formation was evaluated in platelets incubated with scalar concen-
trations of LPS (15–100 pg/ml) and stimulated with or without subthreshold 
concentration (STC) of collagen (0.25 µg/ml) (C) or ADP (2 µmol/l) (D) in pres-
ence or less of TLR4 inhibitor (4 µmol/l) or control peptide (CP) (4 µmol/l) (C 
and D) (n=5) (*p<0.05 for paired analyses; p<0.001 as an overall analysis).
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p38MAPkinase phosphorylation compared to baseline (▶ Figure 
4 A-F). LPS-treated platelets stimulated with STC of collagen or 
ADP showed AKT and p38 phosphorylation (▶ Figure 4 A-F); this 
effect was inhibited in platelets pre-incubated with TLR4 inhibitor 
(▶ Figure 4 A-F).
Finally we investigated if p38MAPKinase inhibition resulted in 
impaired production of platelet eicosanoids; the experiment 
showed that platelet TxB2 and 8-iso-PGF2α -III were significantly 
inhibited in LPS-treated platelets pre-incubated with SB202190, a 
selective inhibitor of p38MAP kinase (▶ Figure 4 G-H).
Figure 3: LPS and platelet oxidative stress. H2O2 production was evalu-
ated in platelets incubated with scalar concentrations of LPS (15–100 pg/ml) 
and stimulated with or without subthreshold concentration (STC) of collagen 
(0.25 µg/ml) (A) or ADP (2 µmol/l) (B) in presence or less of TLR4 inhibitor (4 
µmol/l) or control peptide (CP) (4 µmol/l) (A and B) (n=5) (*p<0.05 for paired 
analyses; p<0.001 as an overall analysis). Nox2 activation was evaluated in 
platelets incubated with scalar concentrations of LPS (15–100 pg/ml) and 
stimulated with or without subthreshold concentration (STC) of collagen 
(0.25 µg/ml) (C) or ADP (2 µmol/l) (D) in presence or less of TLR4 inhibitor (4 
µmol/l) or control peptide (CP) (4 µmol/l) (C and D) (n=5) (*p<0.05 for paired 
analyses; p<0.001 as an overall analysis).
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Figure 4: Intra-signalling pathway of platelet activation by LPS: AKT 
and p38MAPKinase. AKT and p38 phosphorylation was analysed in pla-
telets incubated with scalar concentrations of LPS (15–100 pg/ml) and stimu-
lated with or without subthreshold concentration (STC) of collagen (0.25 
µg/ml) (A-C) or ADP (2 µmol/l) (D-F) in presence or less of TLR4 inhibitor (4 
µmol/l) (A-F) (n=5) (*p<0.05 in quantitative analysis). A representative west-
ern blot of AKT and p38 phosphorylation (A and D). TxB2 production and 
8-iso-PGF2α-III formation was evaluated in platelets pre-treated with LPS 15 
pg/ml and stimulated with subthreshold concentration (STC) of collagen 
(0.25 µg/ml) or ADP (2 µmol/l) in presence or less of SB202190 (5 µmol/l) (G 
and H) (n=5) (*p<0.05 for paired analyses; p<0.001 as an overall analysis).
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Figure 5: Intra-signalling pathway of platelet activation by LPS: 
p47phox, cPLA2. p47phox translocation and cPLA2 phosphorylation was 
analysed in platelets incubated with scalar concentrations of LPS (15–100 
pg/ml) and stimulated with or without subthreshold concentration (STC) of 
collagen (0.25 µg/ml) (A-C) or ADP (2 µmol/l) (D-F) in presence or less of TLR4 
inhibitor (4 µmol/l) or p38 MAPKinase inhibitor SB202190 (5 µmol/l) (A-F) 
(*p<0.05 in quantitative analysis n=5 experiments). A representative west-
ern blot of p47phox translocation and c-PLA2 phosphorylation (A and D). 
[Ca2+]i mobilisation was analysed in platelets incubated with scalar concen-
trations of LPS (15–100 pg/ml) alone or pre-treated with LPS 15 pg/ml and 
stimulated with subthreshold concentration (STC) of collagen (0.25 µg/ml) or 
ADP (2 µmol/l) in presence or less of TLR4 inhibitor (4 µmol/l) (G) (n=5) 
(*p<0.05 for paired analyses; p<0.001 as an overall analysis).
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p47, cPLA2 and [Ca2+]i mobilisation
To analyse the pathway involved in LPS-dependent platelet acti-
vation and oxidative stress, we studied p47phox translocation on pla-
telet membrane, as final and key event upstream of Nox2 acti-
vation, and cPLA2 phosphorylation, a key enzyme for generation 
of eicosanoids and related bioactive lipid mediators.
LPS (15–100 pg/ml)-treated platelets did not affect p47 translo-
cation or cPLA2 phosphorylation compared to control (▶ Figure 
5 A-F). Conversely, in LPS-treated platelets stimulated with STC of 
collagen or ADP, an increase of p47phox cytosol/membrane trans-
location and cPLA2 phosphorylation were detected (▶ Figure 
5 A-F); this effect was significantly inhibited in samples pre-incu-
bated with TLR4 inhibitor and SB202190 (▶ Figure 5 A-F). Finally, 
TLR4 inhibitor did not affect p47 translocation or cPLA2 phos-
phorylation in platelet stimulated with STC of collagen or ADP 
alone (Suppl. Figure 1, available online at www.thrombosis-online.
com).
[Ca2+]i mobilisation is a fundamental step for platelet acti-
vation (19). Compared to platelet alone, LPS up 100 pg/ml or STC 
of agonists slightly but not significantly increased [Ca2+]i mobili-
sation compared to control. LPS (15 pg/ml)-treated platelets 
stimulated with STC of agonists showed a significant increase of 
[Ca2+]i mobilisation, which was blunted in the presence of TLR4 
inhibitor (▶ Figure 5 G).
TLR4 inhibitor did not affect [Ca2+]i mobilisation in platelet 
stimulated with STC of collagen or ADP alone (▶ Figure 5 G).
Apoptosis analysis
To exclude laboratory artefact related to a non-specific activation 
of platelets, we analyses if LPS could determine platelet apoptosis. 
LPS treated-platelets stimulated with STC of either agonist did not 
result in an increase of apoptosis, as assessed by Annexin V mem-
brane expression (▶ Figure 6 A-B).
Ex vivo study
Clinical characteristics of patients with CAP and controls are sum-
marised in Suppl. Table 1 (available online at www.thrombosis-on
line.com).
About two third of CAP patients had moderate-severe CAP as 
assessed by the PSI scoring system, belonging 45 % to PSI class IV 
and 21 % to class V. Compared to controls, CAP patients displayed 
higher urinary levels of 11-dehydro-TxB2 and 8-iso-PGF2α (Suppl. 
Table 1, available online at www.thrombosis-online.com).
Endotoxin serum levels were 145 [115–187] pg/ml in CAP pa-
tients and 18 [6–21] pg/ml in controls (Suppl. Table 1, available 
online at www.thrombosis-online.com); moreover, TLR4 was ex-
pressed significantly more in platelets from CAP compared to con-
trols (▶ Figure 7 A). While control PRP and WP stimulated by 
STC of collagen did not aggregate, PRP and WP from CAP pa-
tients fully aggregated (▶ Figure 7 B-C and Suppl. Figure 2A, avail-
able online at www.thrombosis-online.com) coincidentally with a 
significant increase of 8-iso-PGF2α (▶ Figure 7 D) and TxB2 
(▶ Figure 7 E). Platelet aggregation and eicosanoids production 
Figure 6: Apoptosis analysis. Apoptosis analysis was performed in platelets treated with AA (50 mmol/l) or scalar concentrations of LPS (15–100 pg/ml) 
and stimulated with subthreshold concentration (STC) of collagen (0.25 µg/ml) (A) or ADP (2 µmol/l) (B) (*p<0.05).
Figure 7: LPS in controls and CAP patients. In 10 community-acquired 
pneumonia (CAP) patients and 10 controls, platelet TLR4 expression (A), PA 
(B), 8-iso-PGF2α-III (D) and TxB2 (E) production were evaluated in PRP pre-in-
cubated or not with TLR4bp and stimulated or not with sub-threshold con-
centration (STC) of collagen (n=10) (**p<0.01 and *p<0.05 in quantitative 
analysis for TLR4 expression). Representative tracing of platelet aggregation 
in presence of STC of collagen and TLR4bp (C).
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Figure 8: Schematic 
representation of LPS-
amplified platelet acti-
vation. LPS (15–100 pg/
ml) combined with sub-
threshold concentrations 
of collagen or ADP is able 
to amplify platelet acti-
vation via AKT, p38 and 
cPLA2 phosphorylation 
and p47phox translocation. 
cPLA2 is key enzyme for 
generation of thrombox-
ane (Tx)A2 and 8-iso-
PGF2α-III whereas p47phox 
is a key  cytosolic subunit 
upstream from Nox2 acti-
vation and H2O2 produc-
tion.
were blunted in the presence of TLR4 inhibitor in CAP patients 
(▶ Figure 7 B-E).
In order to support the finding that PA is mediated by increas-
ing TxA2 production, we pre-incubated platelets from CAP pa-
tients with or without 100 µmol/l ASA. The results showed that 
ASA inhibits LPS-mediated platelet aggregation and TxB2 produc-
tion (Suppl. Figure 2B-C, available online at www.thrombosis-on
line.com).
Similar findings were obtained using STC of ADP as agonist 
(data not shown).
Discussion
The results of the present study indicate bacteria-derived LPS as a 
trigger of platelet activation so suggesting a role for LPS in eliciting 
platelet activation in CAP patients.
In the present study, we explored if bacteria-derived LPS is re-
sponsible for platelet activation and the underlying mechanism. Pla-
telets from healthy volunteers were incubated with LPS in a range of 
concentration similar to that found in the blood of CAP; the experi-
ment showed that LPS per se is not an aggregating molecule but is 
able to amplify platelet response to common agonists such as col-
lagen or ADP. This finding parallels the ex vivo study showing that, 
while platelets from healthy subjects did not respond to STC of 
agonists, platelets from CAP patients fully aggregated suggesting 
that an endotoxin-rich milieu may be a trigger for platelet aggre-
gation; in accordance with this, CAP patients disclosed high values 
of blood LPS coincidentally with platelet TLR4 over-expression.
Eicosanoids are a family of molecules derived from enzymatic 
and non-enzymatic oxidation of AA (20). Among them, TxA2, 
which is an unstable product of AA oxidation by COX1, and 8-iso-
PGF2α-III, that is a chemically stable product of arachidonic inter-
action with oxygen free radicals (ROS) (21), elicit PA via a com-
mon receptor (9). Our study shows that both eicosanoids are in-
creased in patients and are implicated in LPS-mediated platelet ag-
gregation as TxB2, the stable metabolite of TxA2, and 8-iso-
PGF2α-III significantly increased in platelets exposed to LPS and 
stimulated with STC of agonists. This finding provides a plausible 
explanation for the ex vivo study where platelets from CAP stimu-
lated with STC of agonists produced more eicosanoids compared 
to controls. The key role played by the two eicosanoids in amplify-
ing the platelet response to the STC of agonists was further sup-
ported by the fact that aspirin or a TXA2 receptor antagonist in-
hibited LPS-mediated PA.
In accordance with previous studies, we confirm that also in 
our experimental model TLR4 is crucial for LPS-mediated PA, as 
the amplification of platelet response to common agonist was no 
more detected in platelets incubated with a TLR4 receptor antag-
onist; similarly, the increase of either TxA2 or 8-iso-PGF2α-III by 
LPS was significantly inhibited by a TLR4 antagonist.
PA by common agonists is associated with a burst of ROS that 
contribute to platelet aggregation via several mechanisms includ-
ing nitric oxide inactivation, ADP release and 8-iso-PGF2α-III 
formation (9, 22, 23). Up-regulation of Nox2, the catalytic sub-unit 
of NADPH oxidase, has a key role in platelet ROS formation as 
shown by almost complete absence of ROS in platelets from pa-
tients with hereditary deficiency of Nox2 (24). In our experimental 
D
ow
nl
oa
de
d 
by
: M
CP
 H
ah
ne
m
an
n 
Un
ive
rs
ity
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Thrombosis and Haemostasis 8/2017 © Schattauer 2017
1569 Nocella, Carnevale, et al. LPS amplifies platelet activation via eicosanoids
What is known about this topic?
• LPS might activate platelets but at concentrations several time 
higher than those found in human circulation.
• Platelet activation has been suggested to play a role in increased 
risk of cardiovascular events in patients with community-acquired 
pneumonia (CAP) but the underlying mechanism is still unclear.
What does this paper add?
• At concentrations detectable in the human blood of CAP patients, 
LPS amplifies the response to common agonists upon interaction 
with Toll-like receptor 4.
• LPS behaves as a pro-thrombotic molecule potentially capable of 
favouring vascular disease.
Abbreviations
8-iso-PGF2α: 8-Iso Prostaglandin F2alpha; AA: arachidonic acid; ACD: 
acid citrate dextrose; ASA: acetylsalicylic acid; CAP: community-ac-
quired pneumonia; COPD: chronic obstructive pulmonary disease; 
CP: control peptide; cPLA2: cytosolic phospholipase A2; PAD: periph-
eral arterial disease; PRP: platelet-rich plasma; ROS: reactive oxygen 
species; sNOX2dp: soluble NOX2-derived peptide; STC: sub-threshold 
concentration; TLR4bp: TLR4 inhibitor; TxB2: Thromboxane B2; WP: 
washed platelet.
model, Nox2-derived ROS seems to be essential for LPS-mediated 
PA as platelet incubation with LPS was associated with ROS over-
production coincidentally with Nox2 activation; both changes 
were inhibited in platelets treated with a TLR4 antagonist suggest-
ing that LPS yields platelet ROS formation via interaction with 
TLR4. As cellular up-stream activation by TLR4 are AKT and p38, 
which are also involved in platelet activation by ADP or collagen 
(20) (▶ Figure 8), we investigated if AKT and p38 were phos-
phorylated by LPS-mediated PA and the role of TLR4 receptor; the 
experiment showed that both were activated by LPS and signifi-
cantly inhibited in platelets incubated with a TLR4 antagonist.
Activation of the AKT-p38MAP kinase axis is of particular in-
terest to explain LPS-mediated PA because this pathway is impli-
cated in Nox2 activation via p47phox translocation to the mem-
brane Nox2; furthermore, this intracellular pathway is involved in 
PLA2 activation, that is essential for AA release from platelet 
membrane and eventually eicosanoid formation (25). In our ex-
perimental model, LPS-mediated PA was associated with either 
p47phox or cPLA2 activation, which likely accounted for the en-
hanced formation of 8-iso-PGF2α-III and TxA2, respectively. 
Thus, p47phox translocation to platelet membrane provides 
further support to the role of Nox2 in platelet ROS formation and 
ultimately 8-iso-PGF2α-III formation while activation of PLA2 is 
crucial for AA release from platelet membrane and ultimately 
TxA2 production (▶ Figure 8).
To explain the synergism between LPS and low doses of platelet 
agonists we focused on intracellular [Ca2+]i mobilisation, which a 
key step for initiation of PA (24). Of interest is the fact that either 
LPS or low doses of agonists slightly increased [Ca2+]i mobili-
sation while a combination of both significantly mobilised intra-
platelet [Ca2+]i, suggesting that this effect is likely to play a pivotal 
role in PA elicited by LPS and STC of agonists.
The results of the present study have implications and limi-
tations. The fact that LPS may activate platelets at concentration 
commonly found in human circulation during infectious disease 
provides further support to the role of LPS as a pro-thrombotic 
molecule in different clinical settings including sepsis or vascular 
diseases complicating the early phase of infections such as CAP 
(26–28).
We did not identify the pathogens responsible for CAP. We can-
not exclude that viruses, which are implicated in CAP more than 
Gram-negative bacteria are also implicated in platelet activation 
detected in CAP patients (29). The enhanced circulating levels of 
circulating of LPS may be dependent upon gut barrier dysfunction 
with ensuing translocation of LPS in the systemic circulation (5); 
this issue should be investigated in the future. Finally, we cannot 
exclude that LPS from other bacteria might have similar effects.
In conclusion, we demonstrated that LPS is a potential stimulus 
for PA via overproduction of TxA2 and 8-iso-PGF2α-III so provid-
ing novel insight into the mechanism accounting for platelet acti-
vation in patients with infectious disease such as those with CAP.
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